Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Releases Positive Top-line Data on Subcutaneous TTR Amyloidosis Drug

Premium

Alnylam Pharmaceuticals this week reported top-line results from an ongoing phase I trial of its subcutaneously administered TTR-mediated amyloidosis treatment ALN-TTRsc, which showed the drug could knock down serum levels of its target protein by more than 80 percent..

The release of the data come about a week after Alnylam presented positive phase II data on an intravenous version of the drug called ALN-TTR02 (GSN 7/3/2013).

ATTR is caused by mutations in the TTR gene, which triggers accumulation of abnormal amyloid proteins in the body. ALN-TTRsc comprises siRNAs designed to inhibit both the wild-type and mutant forms of the protein, and is formulated with Alnylam's proprietary GalNAc conjugate technology.

The ongoing phase I trial is designed to test ALN-TTRsc in up to 40 healthy individuals, who receive single or multiple ascending subcutaneous doses ranging from 1.25 mg/kg to 10 mg/kg. Primary objectives of the study are safety and tolerability, and secondary objectives include assessment of clinical activity as measured by serum TTR levels.

Assuming positive final results from the study, Alnylam anticipates starting a phase II trial in ATTR patients with familial amyloidotic cardiomyopathy – one of the manifestations of the disease – later this year. Phase III testing could begin as soon as 2014.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.